articl
provid
overview
invit
lectur
intern
confer
antivir
research
icar
sponsor
intern
societi
antivir
research
isar
held
rome
itali
may
begin
report
lectur
recipi
isar
three
major
award
held
memori
gertrud
trudi
elion
toni
william
bill
prusoff
follow
summari
three
keynot
address
main
present
within
three
minisymposia
rna
virus
antivir
chemistri
emerg
virus
review
articl
simpli
provid
short
account
oral
present
gener
accompani
refer
scientif
literatur
descript
favor
treatment
outcom
taken
recommend
clinic
use
gener
ad
person
comment
meet
within
conclus
instanc
ad
comment
within
main
text
indic
either
word
use
squar
bracket
one
aim
illustr
great
divers
topic
stimul
think
area
antivir
research
one
strength
icar
gertrud
elion
memori
award
lectur
sofosbuvir
search
cure
phillip
phil
furman
furman
biotech
consult
st
augustin
fl
usa
join
burrough
wellcom
phil
fig
work
trudi
elion
ten
year
time
involv
develop
acyclovir
zovirax
prodrug
valacyclovir
valtrex
phil
join
pharmasset
focu
present
research
pharmasset
lead
identif
activ
sofosbuvir
understand
mechan
action
hepat
c
viru
hcv
phil
account
start
cytidin
analog
fig
one
activ
compound
develop
time
better
roch
idenix
nucleosid
possibl
littl
less
activ
merck
compound
addit
import
factor
lack
detect
cytotox
cc
lm
panel
cell
line
clone
cem
pbm
incident
merck
compound
show
cytotox
cell
line
cc
lm
cem
cell
therefor
reject
contrast
mani
report
cytotox
valu
deriv
hodg
antivir
research
assay
cell
replic
import
compar
effect
compound
replic
viru
replic
cell
order
obtain
valid
therapeut
ratio
metabol
cell
correspond
triphosph
good
inhibitor
hcv
polymeras
inhibit
constant
k
lm
howev
poorli
absorb
oral
signific
convers
inact
uridin
analog
prodrug
approach
collabor
roch
result
increas
bioavail
approach
could
enhanc
short
halflif
h
consid
highli
desir
triphosph
analog
suffici
long
halflif
enabl
onceaday
dose
studi
metabol
cell
note
monophosph
convert
correspond
uridinemp
metabol
uridinetp
uridinetp
analog
less
activ
inhibitor
hcv
polymeras
cytidinetp
analog
k
lm
lm
respect
much
longer
halflif
h
h
respect
long
halflif
h
stimul
interest
research
team
uridin
analog
inact
due
lack
metabol
decid
use
phosphoramid
prodrug
strategi
deliv
cell
phosphoramid
prodrug
first
introduc
chri
mcguigan
former
presid
isar
although
approach
well
known
side
chain
influenc
properti
prodrug
phosphoramid
prodrug
synthes
evalu
cascad
test
particular
interest
everi
success
compound
two
basic
properti
use
efficaci
good
safeti
profil
cascad
start
assay
compar
compound
hcv
replicon
system
vs
ribosomalrna
rrna
cytotox
test
next
step
cytotox
evalu
extens
panel
cell
line
mitochondri
toxic
bone
marrow
toxic
experi
rare
find
compoundscreen
strategi
give
much
emphasi
safeti
profil
compound
test
triphosph
level
pharmacokinet
studi
rat
dog
vivo
rat
toxic
test
prodrug
select
cell
cultur
triphosph
analysi
gave
best
level
human
cell
three
prodrug
test
vivo
initi
rat
pharmacokinet
test
gave
highest
level
liver
measur
either
maximum
concentr
c
max
areaunderthecurv
auc
similarli
best
compound
dog
monkey
activ
evalu
rang
hcv
genotyp
use
replicon
cell
genotyp
sensit
ec
valu
within
also
activ
genotyp
infecti
viru
assay
show
activ
panel
dna
rna
virus
recombin
polymeras
hcv
genotyp
inhibit
ic
valu
lm
respect
result
suggest
would
activ
genotyp
replicon
assay
avail
combin
interferon
rbv
addit
activ
base
evalu
scheme
select
candid
develop
howev
mixtur
two
diastereom
anticip
question
fda
group
decid
separ
isom
rp
isom
found
less
activ
sp
isom
ec
lm
respect
becam
sofosbuvir
fig
sofosbuvir
approv
fda
decemb
eu
januari
later
harvoni
first
day
fixeddos
combin
therapi
hcv
approv
combin
sofosbuvir
ledipasvir
hcv
inhibitor
septemb
estim
usa
patient
receiv
sofosbuvir
part
treatment
cure
hcv
infect
patient
hcv
sofosbuvir
gamechang
memori
award
lectur
novel
therapeut
treat
viral
diseas
cancer
inflammatori
disord
denni
c
liotta
emori
univers
atlanta
ga
usa
memori
late
toni
new
isar
award
medicin
chemistri
announc
icar
piet
herdewijn
first
receiv
award
gave
fascin
talk
entitl
modifi
nucleosid
chemic
modifi
genom
icar
denni
therefor
person
receiv
award
fig
titl
lectur
suggest
denni
gave
us
wonder
account
chemistri
led
new
total
unexpect
direct
current
mani
excel
drug
hiv
therapi
two
approv
drug
target
attach
entri
hiv
cell
maraviroc
pfizer
enfuvirtid
roch
maraviroc
act
antagonist
cellular
receptor
howev
hiv
use
receptor
mtropic
viru
also
receptor
ttropic
viru
major
patient
newli
diagnos
hiv
infect
mtropic
hiv
one
studi
ttropic
viru
initi
untreat
patient
ttropic
viru
emerg
half
patient
averag
time
year
could
maraviroc
therapi
favor
select
ttropic
hiv
import
clinic
implic
ttropic
viru
damag
immun
system
therebi
significantli
p
increas
rate
progress
aid
approv
antagonist
clinic
trial
valid
concept
develop
discontinu
phase
phase
ii
trial
respect
long
time
candid
good
enough
safeti
profil
progress
therapi
hiv
potenti
cancer
chemosensit
outsid
cell
bind
chemosensit
releas
thu
enabl
immun
cell
destroy
cancer
cell
phase
iii
trial
enhanc
effect
chemotherapi
acut
myeloid
leukemia
aml
obtain
similar
compound
effici
gener
synthet
scheme
develop
use
readili
avail
amino
acid
build
block
evalu
compound
sever
cellbas
assay
establish
includ
attach
assay
magi
infect
assay
peripher
blood
mononuclear
cell
pbmc
ttropic
hiv
initi
signal
pathway
via
receptor
also
known
bind
receptor
character
activ
compound
found
activ
assay
radioligand
displac
assay
ilabel
cem
cell
devis
activ
magi
assay
good
druglik
properti
need
optim
aim
becam
appar
potenti
target
consider
sequenc
homolog
similar
ident
crystal
structur
similar
bind
pocket
literatur
dual
activ
start
aldrich
databas
million
compound
use
virtual
screen
bind
top
compound
identifi
compound
purchas
test
magi
yield
compound
activ
lm
activ
lm
one
compound
good
activ
magi
magi
assay
ic
lm
respect
surpris
find
compound
also
activ
nonnucleosid
revers
transcriptas
inhibitor
nnrti
hiv
gener
synthet
rout
similar
compound
shown
three
week
compound
synthes
three
paramet
bind
receptor
nnrti
would
make
structureactivityrel
ship
sar
studi
challeng
decid
focu
bind
two
receptor
compound
fig
select
ic
lm
respect
nnrti
activ
lm
interestingli
displac
assay
effect
even
mm
may
advantag
compound
abl
inhibit
bind
hiv
receptor
unabl
displac
anoth
research
approach
synthes
compound
contain
link
part
tabl
work
led
sever
major
advantag
displac
anoth
compound
bound
displac
crystal
structur
bound
known
show
activ
two
cancer
model
use
mice
preclin
test
toxic
seen
dose
mgkg
dog
monkey
two
phase
ia
trial
complet
singl
ascend
dose
studi
mg
healthi
volunt
daili
dose
late
stage
solid
tumor
patient
toxic
note
trial
latter
trial
woman
fallopian
tube
cancer
complet
remiss
hot
flash
dose
period
therefor
phase
ib
studi
done
women
breast
cancer
take
tamoxifen
patient
drug
year
subject
hot
flash
approv
product
postmenopaus
hot
flash
contraind
cancer
patient
dose
group
mg
show
reduct
hot
flash
encouragingli
subject
complet
respons
go
hot
flashesweek
zero
alongsid
respons
primari
endpoint
improv
variou
secondari
endpoint
drug
good
safeti
profil
mechan
effect
unknown
seem
surpris
antivir
research
program
sourc
first
potenti
therapi
treat
hot
flash
larg
group
women
tamoxifen
therapi
could
predict
would
outcom
erica
describ
intrigu
virus
encod
protein
yet
get
much
function
exampl
filovirus
like
ebola
encod
protein
arenavirus
lassa
encod
protein
yet
protein
perform
function
within
life
cycl
viru
anoth
exampl
filoviru
matrix
protein
respons
assembl
bud
transcript
control
sometim
immunosuppress
done
erica
suggest
one
answer
viral
protein
abl
remodel
repurpos
rearrang
extend
function
complex
erica
show
us
structur
surfac
glycoprotein
gp
ebola
marburg
virus
first
protein
fulli
glycosyl
form
exist
viral
surfac
extens
coat
sugar
residu
hide
part
protein
immun
surveil
complet
fulli
glycosyl
form
bind
receptor
sugarlink
residu
cleav
leav
nake
protein
receptor
bind
site
becom
expos
know
ebola
survivor
effect
antibodi
protect
mani
protein
site
hidden
human
antibodi
obtain
ebola
survivor
antibodi
work
test
tube
mice
guinea
pig
protect
monkey
best
antibodi
ebola
still
way
forward
sever
group
show
combin
antibodi
protect
monkey
exampl
unit
state
armi
medic
research
institut
infecti
diseas
usamriid
cocktail
three
antibodi
two
bind
site
mucin
domain
third
gp
glycan
cap
cleav
endosom
although
cocktail
work
well
vitro
protect
monkey
work
well
vitro
monkey
wherea
work
monkey
vitro
mani
unansw
question
mani
antibodi
best
assay
synergi
resolv
complex
set
unknown
larg
sampl
set
requir
viral
hemorrhag
fever
immunotherapeut
consortium
vhfic
global
collabor
evalu
avail
monoclon
antibodi
mab
ebola
eventu
aim
repeat
later
virus
erica
credit
john
dye
major
player
bring
interest
parti
togeth
form
vhfic
initi
tortois
path
set
sampl
antibodi
sent
erica
laboratori
code
sent
collabor
test
variou
assay
determin
bind
site
initi
result
suggest
antibodi
bind
top
ebola
gp
give
good
neutral
vitro
protect
wherea
antibodi
bind
lower
part
gave
good
neutral
may
protect
parallel
tortois
track
hare
track
initi
use
antibodi
two
current
combin
envisag
focu
structur
determin
vivo
efficaci
could
lead
quickli
reason
efficaci
product
turn
approach
fortuit
case
zero
current
ebola
outbreak
decemb
zmapp
emerg
hare
track
discov
februari
august
zmapp
use
compassion
basi
treat
health
care
worker
repatri
usa
zmapp
consist
three
antibodi
bind
top
gp
recruit
immun
system
bind
base
gp
also
bind
base
gp
latter
two
antibodi
similar
enabl
combin
activ
neutral
test
also
contribut
protect
given
antibodi
antibodi
bind
mucin
necessari
protect
first
month
tortois
approach
mab
much
learnt
mab
bind
variou
part
ebola
gp
number
mab
core
fusion
loop
base
glycan
cap
mucin
mab
still
undefin
usamriid
carri
protect
test
mice
rank
mab
surviv
mice
mab
bind
base
gave
better
protect
similar
mab
zmapp
mab
give
protect
mice
could
consid
inclus
combin
mab
bound
top
core
glycan
cap
mucin
gave
protect
strong
neutral
mab
bound
base
gp
gave
protect
neutral
rough
correl
explan
gp
remodel
mucin
glycan
cap
remov
therefor
core
protein
neutral
exampl
arenaviru
nucleoprotein
np
erica
chose
lassa
viru
erica
compar
np
multifunct
penknifehav
role
nucleocapsid
assembl
immunosuppress
virion
incorpor
regul
polymeras
ntermin
ctermin
domain
open
reveal
new
site
predict
rnabind
site
rna
gate
reveal
surfac
ntermin
domain
open
ssrna
bind
addit
ctermin
domain
role
immunosuppress
fold
becom
exonucleas
abl
digest
dsrna
function
balanc
still
unknown
ebola
marburg
virus
protein
alon
selfassembl
form
viruslik
particl
also
control
transcript
structur
monom
determin
octamer
ring
structur
discov
eight
ntermin
domain
bound
togeth
form
ring
ctermin
domain
center
ring
secmal
light
scatter
devic
use
determin
molecular
weight
protein
prove
exist
dimer
use
mutant
found
butterflyshap
dimer
octamer
ring
essenti
viru
assembl
dimer
assembl
rearrang
form
zigzagshap
hexam
lead
viru
assembl
howev
although
octamer
ring
essenti
viru
assembl
mutant
prevent
octamer
ring
format
nonetheless
lethal
viru
replic
ring
control
transcript
conclus
form
dimer
traffick
cell
octamer
ring
control
transcript
hexam
virion
assembl
tradit
view
gene
encod
protein
fold
protein
abl
perform
one
function
work
ebola
viru
taught
us
although
current
comput
program
follow
tradit
view
natur
use
one
protein
fold
differ
way
perform
differ
function
see
one
gene
encod
one
protein
fold
assembl
three
distinct
form
abl
perform
function
erica
liken
transform
child
toy
robot
refold
becom
truck
one
form
make
rna
transport
virion
look
futur
one
anticip
multifunct
protein
similar
found
virus
pattern
emerg
abl
give
comput
program
new
rule
look
beyond
virus
may
find
may
human
protein
fold
two
form
may
connect
diseas
andor
drug
therapi
raffael
start
present
three
introductori
slide
main
point
highlight
million
peopl
estim
infect
hepat
c
viru
hcv
millionyear
newli
infect
die
year
chronic
infect
vaccin
avail
howev
good
news
hcv
curabl
nuclear
integr
dna
reservoir
latenc
object
therapi
cure
defin
sustain
virolog
respons
svr
patient
remain
hcvfree
week
svr
end
therapi
viru
elimin
associ
reduc
risk
liver
cirrhosi
cancer
third
slide
gave
mileston
therapi
hcv
genotyp
start
interferon
alpha
ifna
cure
rate
pegifna
rbv
addit
proteas
inhibitor
pi
sofosbuvir
usual
anoth
antivir
raffael
gave
detail
introduct
hcv
lifecycl
develop
antivir
compound
main
viral
target
serin
proteas
inhibitor
name
end
previr
protein
creat
hcv
replic
complex
name
end
asvir
rna
polymeras
name
end
buvir
slide
learnt
far
nucleotid
polymeras
inhibitor
good
profil
four
key
paramet
barrier
resist
pangenotyp
efficaci
antivir
potenc
advers
event
provid
justif
focus
nucleotid
analog
hcv
polymeras
inhibitor
summari
report
nucleosidenucleotid
analog
seem
narrow
sar
good
efficaci
hcv
virtual
activ
compound
cmethyl
substitu
appear
narrow
sar
safeti
develop
mericitabin
roch
bm
termin
sofosbuvir
fig
approv
three
other
develop
merck
achillion
janssen
although
structur
disclos
believ
fluoro
substitu
sof
sof
show
high
genet
barrier
resist
vitro
mutant
show
crossresist
cmethyl
nucleotid
resist
sof
modest
mutant
low
viral
fit
although
clinic
signific
resist
sof
previous
report
clinic
trial
fda
analyz
clinic
specimen
nextgener
sequenc
highlight
three
lowfrequ
substitut
associ
sof
failur
one
baselin
polymorph
may
potenti
reduc
sof
efficaci
genotyp
sof
combin
ledipasvir
inhibitor
form
first
singl
pill
regimen
harvoni
hcv
therapi
interest
target
known
enzymat
activ
crucial
format
hcv
membran
web
within
hcv
rna
replic
also
involv
viral
particl
assembl
releas
sever
new
inhibitor
develop
pangenotyp
activ
first
gener
inhibitor
includ
ledipasvir
low
barrier
resist
develop
elbasvir
merck
gilead
higher
barrier
resist
endow
pangenotyp
activ
variou
ifnfre
option
potenti
hcv
therapi
although
differ
combin
efficaci
genotyp
sofcontain
regimen
activ
genotyp
best
sof
daclatasvir
clinic
use
combin
daili
week
show
activ
genotyp
furthermor
initi
data
indic
combin
effect
genotyp
phase
iii
trial
combin
sof
gilead
new
inhibitor
test
oncedaili
dose
week
genotyp
ifnfre
combin
current
test
phase
ii
clinic
trial
aim
develop
today
consid
aspir
regimen
daili
singl
pill
week
svr
genotyp
look
futur
one
envisag
erad
hcv
least
area
remain
seriou
hurdl
one
mani
undiagnos
hcv
infect
current
cost
tend
limit
prescript
patient
advanc
diseas
inclus
patient
may
spread
diseas
becom
import
although
patient
chronic
hepat
b
achiev
function
cure
year
therapi
hepat
c
first
chronic
viral
infect
cure
effici
antivir
compound
seem
svr
treat
patient
within
reach
excit
period
patient
physician
alik
sprecher
san
oper
center
brussel
belgium
san
msf
respond
outbreak
ebola
marburg
hemorrhag
fever
msf
role
current
ebola
outbreak
start
march
alert
ministri
health
guinea
ask
help
outbreak
infect
peopl
led
death
march
msf
team
arriv
day
later
infect
identifi
ebola
march
day
initi
alert
msf
open
ebola
treatment
unit
etu
march
liberian
ministri
health
notifi
msf
four
ebola
death
next
day
msf
set
etu
macenta
guinea
close
border
liberia
next
day
march
four
ebola
case
identifi
conakri
guinea
april
msf
open
etu
conakri
time
msf
sent
staff
field
three
week
later
april
msf
open
etu
liberia
mind
speed
respons
truli
impress
novemb
februari
msf
run
center
guinea
liberia
sierra
leon
total
msf
open
etu
bed
countri
train
peopl
europ
sent
peopl
local
staff
work
center
difficult
distinguish
fever
caus
malaria
ebola
usual
treat
patient
enter
etu
antimalari
drug
peopl
admit
etu
confirm
infect
ebola
viru
also
mass
antimalari
treatment
distribut
peopl
monrovia
million
peopl
freetown
area
anoth
servic
commun
distribut
home
protect
kit
one
notabl
aspect
ebola
outbreak
risk
face
health
care
worker
ever
present
risk
becom
infect
face
hostil
local
commun
guinea
although
msf
staff
threaten
number
occas
forc
withdraw
sometim
staff
suffer
minor
injuri
attack
msf
staff
kill
unfortun
one
incid
led
death
health
care
worker
attack
guinean
health
promot
team
incid
serv
warn
illustr
serious
threat
pose
conspiraci
theori
spread
easili
health
care
worker
difficulti
home
exampl
children
isol
classmat
school
work
protect
gear
stress
heat
exhaust
limit
safe
work
time
min
h
shift
individu
could
expect
work
h
contact
ebola
patient
elabor
protect
procedur
success
greatli
limit
risk
contract
ebola
could
elimin
risk
total
three
intern
staff
becam
infect
evacu
home
countri
surviv
among
local
recruit
staff
although
exposur
link
workplac
event
investig
staff
ill
found
chief
risk
outsid
work
msf
staff
may
famili
friend
infect
ebola
perform
healthcar
activ
outsid
msf
center
natur
peopl
healthcar
worker
known
experi
ebola
often
signific
pressur
home
commun
provid
discreet
servic
total
staff
member
contract
ebola
die
outbreak
msf
care
collect
data
enabl
find
factor
associ
increas
surviv
factor
littl
effect
surviv
rate
includ
malefemal
month
admiss
time
first
symptom
admiss
expect
give
intraven
iv
fluid
would
increas
surviv
foya
etu
week
midjuli
patient
receiv
iv
fluid
suspend
week
larg
increas
new
admiss
week
onward
increas
proport
patient
receiv
iv
fluid
unexpectedli
kaplanmei
surviv
estim
show
benefit
two
factor
increas
chanc
surviv
age
year
age
best
viral
load
baselin
lower
viral
load
greater
chanc
surviv
latter
singl
import
factor
msf
center
particip
clinic
trial
trial
brincidofovir
termin
due
lack
avail
trial
particip
favipiravir
trial
ongo
follow
public
encourag
sign
efficaci
patient
initi
present
either
low
moder
viral
load
trial
convalesc
plasma
recruit
patient
end
april
guinea
frontlin
worker
vaccin
merck
ebola
vaccin
n
end
april
midjun
confirm
case
ebola
infect
patient
care
msf
center
survivor
although
epidem
huge
human
cost
great
joy
everi
time
survivor
leav
go
home
fig
armand
sprecher
conclus
let
advanc
hcv
therapi
michael
mann
hanov
medic
school
hanov
germani
michael
start
present
introduct
hcv
includ
data
confirm
svr
svr
inde
repres
cure
patient
achiev
svr
ifn
therapi
relaps
next
year
sustain
respons
rate
tenyear
period
svr
virtual
elimin
risk
die
due
liverrel
diseas
surviv
compar
ageand
sexmatch
dutch
popul
patient
without
svr
significantli
greater
risk
die
p
wherea
svr
normal
life
span
p
furthermor
symptom
due
hcv
infect
relat
liver
diseas
variou
manifest
limit
profession
social
life
classif
hcv
strain
continu
evolv
recent
special
issu
hepatolog
expand
classif
genotyp
subtyp
therapi
chronic
hcv
infect
develop
sinc
first
hcv
pi
approv
period
addit
pi
pegifna
increas
cure
rate
genotyp
durat
therapi
still
long
week
side
effect
common
treatment
protocol
complex
approv
sof
durat
therapi
pegifnasof
week
cure
rate
approach
also
simeprevir
smv
pi
activ
genotyp
daclatasvir
inhibitor
activ
genotyp
sofledipasvir
harvoni
genotyp
approv
variou
antivir
combin
allow
explor
ifnfre
therapi
hanov
januaryjun
sofrbv
n
compar
pibas
therapi
n
overal
cure
rate
sofrbv
fig
msf
staff
member
share
celebr
joy
depart
patient
recov
ebola
msf
patient
leav
handprint
survivor
wall
imag
peter
casaer
publish
permiss
much
higher
pi
therapi
due
patient
elig
treatment
vs
better
adher
vs
better
svr
vs
respect
septemb
survey
patient
usa
europ
german
site
patient
sofsmv
sofpegifnarbv
sofsmvrbv
sofrbv
sof
becom
backbon
therapi
chronic
hepat
c
combin
ombitasvirparitaprevirritonavir
genotyp
dasabuvir
nonnucleosid
inhibitor
hcv
polymeras
genotyp
approv
therapi
genotyp
therapi
ombitasvirparitaprevir
dasabuvir
gave
svr
similar
achiev
harvoni
latter
simpl
one
pillday
treatment
treatment
guidelin
chang
rapidli
european
associ
studi
liver
easl
guidelin
april
supersed
april
treatment
priorit
patient
signific
liver
diseas
coinfect
hiv
hbv
debilit
fatigu
risk
transmit
hcv
choic
therapi
depend
sever
factor
perhap
import
genotyp
stage
liver
diseas
moder
compens
sever
decompens
cirrhosi
prefer
treatment
option
usual
includ
sof
hardesttotreat
patient
genotyp
cirrhosi
patient
option
may
better
even
includ
pegifna
least
present
also
patient
renal
insuffici
ombitasvirparitaprevir
dasabuvir
prefer
option
sof
daclatasvir
pegifnasof
genotyp
look
ahead
grazoprevirelbasvir
combin
complet
phase
iii
trial
seem
well
toler
patient
renal
insuffici
includ
dialysi
hcv
resist
emerg
problem
ledipasvir
compon
harvoni
patient
treat
ledipasvir
without
sof
essenti
patient
end
treatment
resist
viru
seem
fulli
compet
mutant
viru
persist
week
therapi
howev
new
inhibitor
velpatasvir
gs
activ
genotyp
hcv
strain
mutant
resist
ledipasvir
also
appear
high
genet
barrier
resist
velpatasvir
use
sof
fixeddos
combin
pill
approv
grazoprevirelbasvir
sofvelpatasvir
expect
earli
second
nucleosid
analog
receiv
approv
late
hcv
therapi
may
seem
possibl
patient
hcv
infect
long
liver
diseas
sever
treatabl
virtual
patient
achiev
cure
initi
durat
therapi
like
week
week
look
possibl
patient
group
far
therapi
week
given
substanti
reduc
proport
cure
novel
approach
use
microrna
inhibitor
intern
confer
antivir
research
icar
held
san
francisco
california
present
miravirsen
vere
within
utr
hcv
two
sixnucleotid
region
known
seed
site
site
highli
conserv
genotyp
hcv
bind
host
microrna
present
liver
cell
interact
prevent
degrad
viral
rna
therebi
enabl
hcv
replic
miravirsen
oligonucleotid
contain
block
base
cc
att
g
tca
ca
ct
c
bind
prevent
bind
viral
rna
small
phase
ii
studi
mean
reduct
viral
load
log
patient
becam
hcv
rna
undetect
similar
approach
singl
dose
mgkg
administ
sc
inject
placebo
control
phase
ii
trial
n
genotyp
week
mean
viral
load
reduct
log
log
respect
notabl
seven
patient
remain
hcv
rna
neg
week
followup
conclus
chronic
hcv
infect
becom
curabl
diseas
use
welltoler
simpl
daili
antivir
therapi
present
main
barrier
increas
treatment
uptak
cost
one
may
anticip
cost
declin
consid
uptak
franc
one
higher
rate
uptak
one
calcul
franc
much
reduc
hcvinfect
popul
within
near
futur
prospect
abl
treat
cure
virtual
highprior
patient
hope
new
therapi
expect
make
easier
treat
patient
irrespect
genotyp
one
consid
mani
potenti
hcv
mutant
aris
everi
day
untreat
patient
progress
antivir
therapi
remark
achiev
minisymposium
rna
virus
cruis
noroviru
progress
challeng
antivir
drug
discoveri
joana
rochapereira
rega
institut
medic
research
leuven
belgium
norwalk
ohio
usa
bacteriafre
filtrat
shown
caus
gastroenter
eventu
small
viru
particl
nm
visual
clone
norwalk
viru
genom
show
viru
belong
famili
calicivirida
broadli
reactiv
rtpcr
taqman
assay
becam
avail
norovirus
known
major
caus
epidem
gastroenter
food
born
ill
although
noroviru
outbreak
cruis
ship
get
lot
public
usa
outbreak
longterm
care
home
cruis
ship
vulner
popul
elderli
increas
risk
hospit
death
children
symptom
last
day
viru
shed
continu
week
immunocompromis
chronic
gastroenter
may
last
month
year
countri
routin
rotaviru
vaccin
norovirus
major
caus
sever
childhood
diarrhea
easi
understand
outbreak
semiclos
environ
difficult
control
quickli
becom
extens
wherea
infecti
dose
viru
particl
symptomat
patient
may
shed
viru
particlesg
stool
shed
persist
day
addit
individu
may
asymptomat
shed
viru
albeit
less
still
mani
time
infecti
dose
gut
microbiota
could
import
role
infect
infecti
particl
remain
surfac
week
virtual
individu
suscept
due
great
divers
strain
lack
longlast
immun
vaccin
use
recombin
protein
form
viruslik
particl
rvlp
base
selfassembl
shown
slight
efficaci
major
challeng
remain
crossprotect
mani
strain
durat
immun
approv
drug
treat
noroviru
infect
possibl
assay
test
potenti
therapi
use
murin
noroviru
mnv
investig
wildtyp
mice
mnv
give
asymptomat
infect
mice
innat
immun
defici
diarrhea
either
acut
chronic
two
compound
use
evalu
assay
cmethylcytidin
favipiravir
prodrug
valopicitabin
develop
antihcv
drug
favipiravir
licens
japan
influenza
treatment
phase
iii
usa
mnv
cell
cultur
assay
activ
ec
lm
favipiravir
poorli
activ
acut
mnv
infect
administ
h
infect
gave
protect
vs
survivor
control
group
decreas
protect
given
h
pi
surviv
respect
chronic
infect
administ
day
day
day
day
treatment
show
good
reduct
viral
load
return
control
level
treatment
essenti
inact
mnv
assay
would
good
posit
control
develop
antivir
prevent
rabi
anthoni
fook
anim
plant
health
agenc
weybridg
uk
ever
sinc
pasteur
rabi
vaccin
deriv
rabbit
spinal
cord
time
postexposur
prophylaxi
pep
success
protect
subject
clinic
diseas
sempl
fuenzalida
vaccin
use
kill
viru
deriv
sheep
brain
mous
brain
respect
vaccin
use
wide
longer
recommend
rabi
viru
grown
cell
cultur
inactiv
use
current
vaccin
promot
good
antibodi
respons
better
safeti
profil
tissuederiv
vaccin
rabi
normal
transmit
infect
mammal
via
bite
often
muscl
incub
period
variabl
week
year
usual
month
long
incub
period
enabl
pep
protect
subject
clinic
diseas
viru
get
brain
mortal
essenti
worldwid
million
peopl
receiv
pep
year
nevertheless
die
rabi
major
receiv
pep
countri
vaccin
cost
remain
limit
factor
exposur
sever
vaccin
immunoglobulin
administ
rais
cost
substanti
cost
reduc
avail
increas
one
approach
use
plant
produc
monoclon
antibodi
mab
potenti
advantag
includ
reduc
risk
contamin
animalhuman
pathogen
although
mab
plantspecif
glycan
neutral
rabi
viru
effici
origin
mab
hamster
inocul
rabi
viru
leg
muscl
treat
plantderiv
antibodi
h
post
infect
pi
without
coadministr
rabi
vaccin
day
pi
survivor
respect
compar
control
group
two
mab
neutral
broad
rang
viru
isol
potenti
combin
mab
therapi
bind
differ
epitop
although
potenti
grow
transgen
plant
develop
countri
would
great
advantag
abl
use
exist
oral
antivir
compound
sever
approach
tri
without
success
favipiravir
licens
japan
influenza
therapi
known
activ
mani
rna
virus
cell
cultur
assay
provid
first
evid
activ
favipiravir
rabi
viru
preliminari
test
mice
viru
inocul
directli
brain
essenti
protect
provid
favipiravir
treatment
howev
certainli
sever
test
repres
human
clinic
situat
incub
period
commonli
month
hope
evalu
favipiravir
continu
one
build
experi
favipiravir
use
treat
patient
ebola
infect
current
outbreak
west
africa
use
safe
higher
dose
influenza
infect
indic
favipiravir
therapi
benefici
patient
whose
level
ebola
viru
time
present
low
moder
possibl
may
true
patient
rabi
viru
infect
exposur
less
sever
aed
mosquito
spread
denv
seem
due
spread
mosquito
serotyp
denv
prior
infect
one
serotyp
protect
serotyp
may
enhanc
sever
infect
anoth
serotyp
via
antibodyenhanc
entri
viru
cell
clinic
symptom
rang
mild
sever
global
burden
estim
million
sever
case
lead
death
current
treatment
support
care
tetraval
vaccin
test
young
children
latin
america
asia
partial
effect
prevent
clinic
diseas
effect
prevent
seriou
diseas
addit
would
use
avail
treatment
help
patient
sever
diseas
typic
viru
load
alreadi
declin
time
patient
seriou
symptom
howev
clinic
trial
show
use
steroid
benefici
balapiravir
nucleosid
analog
develop
hcv
stop
due
safeti
concern
patient
weeksmonth
therapi
trial
balapiravir
show
benefit
denv
infect
similarli
potenti
antivir
evalu
clinic
trial
although
none
efficaci
trial
given
oxford
univers
clinic
research
unit
good
experi
organ
trial
great
potenti
collabor
group
exampl
univers
marseil
explor
inhibitor
viral
rnadepend
rna
polymeras
medic
school
hannov
germani
hepat
e
viru
hev
first
describ
waterborn
hepat
design
hev
hev
spheric
positivestrand
rna
viru
belong
famili
hepevirida
viru
code
proteas
helicas
polymeras
potenti
antivir
target
genotyp
genotyp
infect
human
one
serotyp
europ
usa
common
genotyp
genotyp
particularli
sever
pregnant
women
india
asia
genotyp
common
germani
casesyear
sinc
number
case
increas
worldwid
hev
infect
caus
death
year
hev
genotyp
detect
variou
mammal
includ
pig
increas
seropreval
individu
contact
pig
transmiss
hev
via
pork
meat
record
gener
immunocompet
popul
hev
usual
caus
mild
moder
selflimit
diseas
howev
immunocompromis
patient
transplant
patient
preval
chronic
hev
progress
cirrhosi
within
year
like
lead
death
diagnost
test
hev
variabl
qualiti
exampl
hev
rtpcr
assay
compar
use
sampl
known
contain
hev
detect
rate
implic
test
blood
donat
blood
product
annual
incid
hev
infect
blood
donor
germani
preval
transmiss
studi
southeast
england
note
preval
hev
genotyp
popul
includ
blood
donor
unknown
probabl
widespread
hev
detect
pool
plasma
sampl
ribavirin
rbv
use
treat
hev
infect
patient
case
seri
hannov
one
patient
sever
acut
infect
genotyp
patient
chronic
hepat
genotyp
treat
rbv
mgday
month
nine
patient
achiev
svr
one
relaps
one
develop
resist
viru
interestingli
hevmut
increas
viral
fit
larger
studi
n
median
durat
rbv
therapi
month
major
patient
achiev
svr
unfortun
rbv
use
contraind
pregnant
women
anoth
compound
appar
activ
hev
mycophenol
chronic
hev
seen
heart
transplant
patient
receiv
mycophenol
one
serotyp
vaccin
hev
seem
realist
possibl
recombin
hev
vaccin
rhev
contain
capsid
protein
develop
glaxosmithklin
gsk
evalu
phase
ii
trial
vaccin
administ
month
subject
follow
day
primari
endpoint
number
confirm
hev
infect
day
vaccin
dose
subject
hev
vaccin
group
placebo
group
p
efficaci
vaccin
unfortun
vaccin
progress
phase
iii
trial
china
attenu
viru
vaccin
evalu
larg
phase
iii
trial
n
group
subject
follow
month
first
dose
subject
hev
infect
vaccin
group
placebo
group
p
vaccin
efficaci
although
vaccin
avail
china
seem
plan
evalu
vaccin
usa
europ
howev
world
health
organ
recent
publish
statement
hepat
e
vaccin
posit
paper
may
factsheet
updat
juli
conclus
due
lack
suffici
inform
safeti
immunogen
efficaci
follow
popul
subgroup
recommend
routin
use
vaccin
children
age
year
pregnant
women
chronic
liver
diseas
patient
patient
organ
transplant
wait
list
travel
may
special
situat
outbreak
risk
hepat
e
complic
mortal
particularli
high
current
posit
concern
routin
programm
preclud
use
vaccin
specif
situat
seem
littl
prospect
vaccin
becom
wide
avail
forese
futur
ribavirin
use
certain
high
need
patient
exampl
pregnant
women
therefor
urgent
need
safer
efficaci
drug
treat
hev
infect
hepat
c
viru
entri
inhibitor
thoma
baumert
univers
strasbourg
strasbourg
franc
mann
describ
excit
advanc
antivir
therapi
treat
chronic
hepat
c
although
current
therapi
give
high
cure
rate
mani
case
cure
rate
rather
lower
patient
genotyp
andor
advanc
liver
diseas
hope
new
combin
sof
velpatasvir
approv
target
date
earli
effect
treat
patient
genotyp
patient
advanc
liver
diseas
liver
transplant
remain
option
univers
reinfect
graft
transplant
hcv
quasispeci
evolv
gener
hcv
variant
enhanc
effici
viral
entri
cell
alter
receptor
use
poorli
neutral
patient
antibodi
viral
entri
regard
good
target
prevent
therapi
liver
graft
infect
sever
host
protein
involv
entri
hcv
cell
antibodi
one
shown
promis
efficaci
good
safeti
profil
antibodi
prevent
infect
cell
cultur
model
show
strong
synergi
antivir
compound
effect
genotyp
although
genotyp
requir
tenfold
higher
dose
genotyp
variou
function
assay
reveal
toxic
upascid
mice
graft
human
hepatocyt
express
local
similar
human
liver
scid
mous
model
use
sever
proofofconcept
studi
test
prevent
infect
lg
administ
intraperiton
ip
inject
time
infect
hcv
genotyp
twice
first
week
good
circul
level
middl
second
week
reduc
almost
baselin
week
control
group
mice
rapidli
increas
hcv
load
first
two
week
reach
plateau
week
mice
treat
undetect
hcv
level
week
test
efficaci
scid
mice
chronic
infect
hcv
genotyp
administ
weekli
dose
lg
ipdos
control
mice
n
hcv
load
remain
high
treat
group
n
viral
load
becam
undetect
fourweek
treatment
period
mice
hcv
remain
undetect
week
singl
mous
mab
level
low
may
account
relaps
end
therapi
howev
viru
show
resist
use
model
monotherapi
shown
activ
genotyp
emerg
resist
sign
toxic
longer
treatment
time
week
result
elimin
hcvinfect
hepatocyt
mous
model
good
efficaci
appear
due
abil
inhibit
cellcel
transmiss
time
hcvinfect
cell
replac
new
uninfect
cell
envisag
therapi
offer
effici
safe
antivir
strategi
possibl
combin
antivir
compound
prevent
liver
graft
infect
think
broadli
approach
may
use
treat
infect
caus
virus
dengu
coxsackieviru
adenoviru
develop
antivir
respiratori
syncyti
viru
john
de
vincenzo
univers
tennesse
memphi
tn
usa
respiratori
syncyti
viru
rsv
highli
success
viru
infect
virtual
everi
child
year
age
worldwid
autumn
peak
season
rsv
infect
usa
ongo
trial
evalu
potenti
link
asthma
rsv
hospit
long
time
uncertainti
whether
symptom
rsv
infect
caus
directli
viru
via
induc
stimul
immun
system
recent
work
shown
mani
respiratori
cell
contain
rsv
cell
cilia
becom
infect
big
influx
immun
inflammatori
cell
viru
load
peak
day
start
symptom
viral
load
predictor
hospit
viru
clearanc
associ
recoveri
find
led
conclus
rsv
directli
caus
diseas
therefor
potenti
role
antivir
therapi
although
window
opportun
remain
uncertain
palivizumab
mab
bind
fusion
protein
rsv
first
drug
licens
prevent
rsv
infect
motavizumab
close
relat
palivizumab
improv
bind
fusion
protein
mab
effect
prevent
rsv
diseas
role
reduc
establish
diseas
still
uncertain
fig
inhibitor
rsv
fusion
protein
good
oral
avail
rang
rat
dog
lungplasma
areaunderthecurv
auc
ratio
rat
exhibit
potent
vitro
activ
rsv
b
clinic
isol
mean
ec
nm
experiment
viral
challeng
trial
healthi
adult
volunt
inocul
wellcharacter
strain
rsv
day
incub
period
vari
day
volunt
monitor
first
detect
viru
upper
respiratori
tract
usual
occur
day
post
inocul
therapi
start
h
first
detect
viru
nasal
wash
evalu
doserang
challeng
studi
volunt
compris
dose
group
one
placebo
group
viral
load
mucu
weight
total
symptom
score
measur
oral
dose
daili
reduc
rsv
replic
suppress
infectionassoci
clinic
symptom
dosedepend
manner
dose
drug
day
initi
dose
mg
follow
dose
mg
produc
strongest
therapeut
effect
peak
viral
load
suppress
log
reduc
auc
clinic
symptom
compar
placebo
treatment
oral
prodrug
nucleosid
analog
fig
inhibit
rsv
polymeras
similar
volunt
challeng
studi
treatment
start
h
viru
detect
pcr
day
inocul
whichev
first
although
volunt
random
placebo
subject
met
criterion
infect
intentiontotreat
popul
three
dose
regimen
administ
twice
daili
day
mg
dose
mg
load
dose
ld
mg
mainten
dose
md
mg
mg
md
placebo
group
viral
load
high
pfuml
day
day
reduc
slowli
day
similarli
symptom
score
peak
day
reduc
slowli
day
dose
show
good
activ
three
paramet
viral
load
mucu
weight
symptom
score
mean
time
nondetect
rsv
rna
day
treatment
group
compar
day
placebo
group
particularli
note
load
dose
reduc
viral
load
immedi
log
h
contrast
fusion
inhibitor
reduc
viral
load
initi
increas
h
seem
well
toler
report
demonstr
high
barrier
develop
viral
resist
alio
biopharma
inc
press
releas
octob
volunt
challeng
studi
seem
confirm
symptom
caus
rsv
directli
due
viru
polymeras
inhibitor
abl
significantli
reduc
viral
load
symptom
score
p
p
respect
ongo
phase
ii
studi
young
children
hospit
rsv
infect
anoth
volunt
studi
rsv
influenza
compar
viral
load
symptom
score
increas
later
rsv
influenza
suggest
window
opportun
antivir
therapi
greater
infect
rsv
influenza
minisymposium
antivir
chemistri
design
synthesi
biolog
evalu
human
inhibitor
multipl
antivir
activ
maurizio
botta
degli
studi
di
siena
siena
itali
one
human
deadbox
rna
helicas
contain
conserv
motif
amino
acid
sequenc
dead
aspglualaasp
gave
famili
protein
name
deadbox
focu
present
investig
potenti
antivir
benefit
could
obtain
inhibit
cellular
cofactor
potenti
benefit
easi
identifi
involv
sever
viral
infect
mechan
hiv
newli
synthes
viral
rna
export
nuclear
membran
via
bind
hcv
interact
viral
core
protein
help
build
nucleocapsid
japanes
enceph
viru
jev
bind
viral
rna
replic
poxviru
bind
viral
protein
essenti
overcom
ifnmedi
cellular
respons
west
nile
viru
wnv
dengu
viru
dnv
depend
although
mechan
known
harm
effect
may
caus
inhibit
implic
play
role
variou
process
includ
rna
metabol
transcript
splice
mrna
nuclear
export
translat
howev
two
encourag
find
overexpress
sever
aggress
cancer
knockdown
inhibit
hiv
replic
seem
affect
cell
viabil
two
site
particular
interest
atpas
bind
site
typic
helicas
catalyt
site
crystal
structur
known
protein
open
form
two
subdomain
connect
flexibl
linker
one
domain
atpas
bind
site
typic
conserv
motif
helicas
distribut
two
domain
construct
model
close
conform
two
approach
tri
start
human
protein
homolog
drosophila
vasa
equival
model
result
first
approach
enough
space
rna
strand
second
approach
led
model
rna
strand
fit
perfectli
use
silico
screen
commerci
databas
led
sever
hit
atpas
site
helicas
site
latter
seem
potenti
achiev
select
inhibit
major
focu
optim
compound
bind
helicas
site
sever
compound
inhibitor
inact
inhibitor
three
activ
compound
inhibit
least
two
panel
virus
one
result
virus
first
demonstr
small
molecul
abl
target
activ
site
inhibit
activ
also
first
time
singl
inhibitor
shown
activ
differ
virus
although
good
demonstr
concept
assess
safeti
import
compar
like
like
inhibit
viral
replic
inhibit
cellular
replic
especi
hiv
hcv
safeti
profil
current
drug
set
high
standard
would
match
new
therapi
studi
still
ongo
direct
hand
approach
may
lead
anticanc
treatment
interest
data
receiv
publish
due
cours
triphosph
prodrug
tripppro
biolog
activ
nucleosid
analog
chri
meier
univers
hamburg
hamburg
germani
previou
icar
chri
report
cyclos
approach
deliv
nucleosid
monophosph
nmp
cell
although
mani
compound
poor
antivir
activ
due
ineffici
phosphoryl
monophosph
mp
limit
step
may
phosphoryl
dior
triphosph
dp
tp
focu
present
develop
strategi
synthes
prodrug
nucleosidetriphosph
ntp
ntp
fulli
mask
becom
chemic
labil
water
chemic
stabil
much
improv
charg
alpha
beta
b
phosphoru
atom
initi
eas
synthesi
termin
phosphoru
protect
two
ident
mask
group
aqueou
phosphat
buffer
salin
pb
essenti
ntp
form
h
predomin
form
h
incub
pig
liver
esteras
first
mask
group
remov
within
min
second
much
slowli
h
predomin
form
ntp
small
amount
ndp
although
symmetr
tripppronucleotid
abl
penetr
cell
high
lipophil
associ
desir
high
transport
cell
also
high
stabil
led
greater
amount
nmp
ndp
two
differ
mask
group
one
highli
lipophil
less
esteras
cleav
less
lipophil
group
first
quickli
follow
chemic
cleavag
remain
part
mask
group
creat
charg
termin
phosphoru
atom
second
ester
cleav
specif
tp
format
high
demonstr
approach
one
mask
group
methyl
group
c
h
fig
prodrug
incub
cell
extract
min
methyl
ester
cleav
min
form
essenti
similarli
ch
c
h
dipproaztdp
prepar
test
compar
symmetr
c
h
dipproaztdp
ratio
aztdpaztmp
respect
recent
compar
result
obtain
case
triphosph
deriv
nonsymmetr
deriv
gave
better
select
deliveri
tp
versu
dp
demonstr
mask
ntp
enter
cell
regener
ntp
insid
cell
symmetr
c
h
trippprobcnatp
fig
incub
cem
cell
lymphoblastoid
tcell
line
incub
min
consider
amount
bcnatp
detect
cell
extract
addit
bcnadp
incub
min
bcnatp
dephosphoryl
give
bcnadp
major
product
well
amount
bcnamp
contrast
incub
parent
nucleosid
bcna
give
trace
phosphoryl
bcna
metabolit
parent
nucleosid
detect
unsymmetr
version
bcnatp
synthes
evalu
denv
polymeras
attract
target
antivir
protein
contain
polymeras
conserv
protein
among
four
serotyp
denv
although
crystal
structur
free
denv
polymeras
known
polymeras
bound
templat
nascent
rna
strand
ternari
complex
crystal
aim
project
creat
model
ternari
complex
denv
polymeras
explor
conform
chang
polymeras
initi
elong
viral
rna
start
point
crystal
structur
ternari
complex
hcv
polymeras
templat
nascent
rna
strand
import
hcv
polymeras
denv
polymeras
two
mg
ion
ad
activ
site
model
refin
via
energi
minim
model
valid
dock
known
polymeras
inhibitor
model
stabil
confirm
molecular
dynam
md
simul
mg
ion
nucleic
acid
appear
well
posit
model
ternari
complex
free
denv
polymeras
crystal
structur
two
loop
loop
residu
loop
b
residu
unknown
structur
known
prime
loop
model
initi
complex
first
two
mg
ion
ad
activ
site
model
loop
b
built
accord
amino
acid
sequenc
prime
loop
residu
model
presenc
short
doublestrand
ds
rna
final
addit
singlestrand
ss
rna
introduc
put
tunnel
ssrna
templat
enter
activ
site
encircl
three
loop
includ
b
next
step
includ
longer
dsrna
model
repres
elong
phase
prime
loop
remodel
accommod
complex
submit
md
simul
specif
residu
prime
loop
gain
contact
nascent
rna
strand
model
indic
chang
conform
loop
especi
loop
prime
loop
play
import
role
enabl
polymeras
perform
differ
function
requir
replic
viral
rna
synthesi
initi
elong
result
like
help
design
denv
polymeras
inhibitor
chikungunya
viru
chikv
first
isol
patient
tanzania
sinc
success
outbreak
africa
first
document
epidem
asia
bangkok
chikv
viru
spread
india
much
tropic
southeast
asia
la
island
east
madagascar
french
territori
health
care
compar
franc
first
case
chikv
infect
occur
februari
outbreak
peak
may
casesweek
follow
januari
epidem
spread
rapidli
peak
end
januari
casesweek
june
case
island
popul
extens
outbreak
area
good
health
facil
clinic
aspect
previous
suspect
eg
myocard
confirm
aspect
newli
observ
eg
neurolog
form
children
also
adult
fulmin
hepat
renal
failur
elderli
patient
slightli
increas
risk
mortal
gener
patient
recov
although
sever
arthralgia
may
persist
month
even
year
mani
genotyp
chikv
relat
three
major
lineag
eastern
central
south
african
ecsa
includ
indian
sublineag
ii
asian
lineag
iii
west
african
lineag
latter
never
produc
larg
outbreak
sporad
case
common
host
chikv
aed
aegypti
restrict
tropic
region
aed
albopictu
surviv
slightli
cooler
region
januari
europ
ae
aegypti
establish
coastal
region
around
east
black
sea
portugues
island
madeira
januari
ae
albopictu
invad
becom
establish
first
north
east
costal
region
itali
spread
much
mediterranean
coast
spain
greec
within
ecsa
lineag
import
mutat
particular
glycoprotein
increas
viral
replic
mosquito
ae
albopictu
expand
rang
ae
albopictu
present
chikv
new
opportun
chikv
known
circul
europ
singl
individu
return
itali
india
led
outbreak
case
septemb
first
two
local
case
record
southeastern
franc
follow
cluster
case
montpelli
franc
least
recent
time
see
chikv
report
new
world
novemb
caribbean
island
st
martin
five
patient
denguelik
fever
later
shown
chikv
infect
asian
lineag
although
asian
lineag
chikv
initi
strain
new
world
ecsa
lineag
recent
identifi
caus
larg
outbreak
brazil
concomitantli
today
million
case
new
world
also
potenti
caribbean
chikv
spread
franc
import
case
known
region
franc
ae
albopictu
present
account
chikv
end
unexpect
twist
viru
spread
caribbean
america
previous
may
chikv
epidem
record
henri
dickson
professor
medicin
south
carolina
usa
recent
public
halstead
propos
epidem
call
dengu
characterist
chikv
anna
papa
aristotl
univers
thessaloniki
thessaloniki
greec
present
anna
highlight
follow
virus
crimeancongo
hemorrhag
fever
viru
cchfv
tickborn
enceph
viru
tbev
west
nile
viru
wnv
phlebovirus
virus
cchfv
member
famili
bunyavirida
rna
genom
segment
design
l
transmiss
bite
infect
tick
main
vector
hyalomma
marginatum
direct
contact
blood
tissu
virem
patient
livestock
variou
environment
factor
influenc
tick
surviv
abund
infect
season
march
novemb
group
higher
risk
infect
contact
livestock
cours
diseas
incub
period
day
fever
peak
viremia
next
day
follow
hemorrhag
phase
peak
day
later
fatal
rate
specif
treatment
option
although
ribavirin
routin
use
clinic
efficaci
unproven
fda
approv
treatment
favipiravir
may
better
option
highli
potent
cell
cultur
vivo
anna
briefli
mention
report
use
mous
model
oestereich
et
al
placebotr
mice
die
day
post
infect
pi
cchfv
pfu
ribavirin
surviv
time
prolong
surviv
rate
increas
favipiravir
first
test
high
dose
mgkg
twice
daili
oral
start
h
day
day
pi
end
day
treatment
protect
mice
fulli
essenti
evid
infect
diseas
treatment
start
day
pi
minor
chang
weight
temperatur
aspart
amino
transferas
ast
detect
day
thereaft
viru
remain
undetect
blood
organ
three
group
throughout
observ
period
provid
evid
infect
anim
favipiravir
treatment
group
develop
cchfvspecif
antibodi
investig
day
pi
anim
treat
h
pi
develop
antibodi
wherea
anim
treat
day
pi
develop
antibodi
dose
rang
studi
favipiravir
mgkg
administ
oral
twice
daili
start
h
pi
continu
day
higher
dose
gave
good
protect
detect
viru
blood
throughout
observ
period
viru
organ
day
essenti
clinic
sign
infect
howev
lower
dose
margin
activ
prolong
surviv
time
chang
surviv
rate
author
conclud
data
hold
promis
clinic
efficaci
favipiravir
human
cchf
wide
approv
vaccin
formalininactiv
mousebrain
viru
use
bulgaria
novel
vaccin
entir
open
read
frame
orf
msegment
cchfv
insert
vaccinia
viru
shown
protect
mice
lethal
challeng
buttigieg
et
al
studi
low
pathogen
greek
cchfv
strain
may
give
insight
vaccin
develop
isol
rhipicephalu
bursa
tick
goat
vergina
greek
villag
relat
strain
kosovo
albania
turkey
seem
caus
littl
symptom
seropreval
greec
area
area
even
higher
mountain
region
western
greec
tbev
belong
famili
flavivirida
two
type
eastern
subtyp
russian
vector
ixod
persulcatu
caus
sever
diseas
mortal
ii
western
subtyp
central
europ
vector
ixod
ricinu
caus
milder
diseas
mortal
ixod
ricinu
wide
distribut
europ
diseas
cours
incub
day
fever
next
day
neurolog
symptom
next
ca
week
follow
recoveri
vaccin
avail
episod
gave
good
illustr
quick
collabor
hospit
research
laboratori
august
physician
thessaloniki
hospit
note
unusu
high
number
enceph
case
next
day
sampl
sent
refer
laboratori
case
shown
posit
wnv
night
august
mosquito
trap
set
posit
pcr
test
achiev
august
mutat
protein
previous
associ
increas
pathogen
neuroinvas
human
compar
strain
follow
observ
report
case
west
nile
neuroinvas
diseas
wnnd
greec
collect
averag
number
case
casesyear
total
case
year
fatal
bring
phlebovirus
belong
famili
bunyavirida
diseas
vari
asymptomat
seriou
cn
infect
depend
viru
sever
novel
phlebovirus
detect
mediterranean
region
greec
virus
report
diseas
season
greec
april
octob
small
studi
patient
fever
cn
infect
test
phleboviru
infect
period
patient
phleboviru
infect
although
proport
patient
cn
infect
vari
year
year
mani
tickborn
phlebovirus
found
mediterranean
countri
phlebovirus
belong
famili
bunyavirida
cchfv
possibl
favipiravir
may
good
activ
phlebovirus
favipiravir
report
show
efficaci
rift
valley
fever
rodent
model
middl
east
respiratori
syndrom
mer
bart
haagman
erasmu
mc
netherland
cov
normal
caus
symptom
typic
common
cold
novemb
saw
appear
sever
acut
respiratori
diseas
becam
known
sar
via
air
travel
sar
quickli
spread
around
globe
novemb
juli
probabl
case
report
outbreak
control
identif
quarantin
isol
yearold
saudi
male
fever
cough
pneumonia
studi
new
cov
mer
detect
contrast
sar
new
viru
spread
rapidli
march
march
virtual
confirm
case
mer
middl
east
europ
rest
world
case
mer
middl
east
probabl
sourc
infect
concern
death
larg
peak
report
case
aprilmay
otherwis
normal
casesmonth
fact
human
case
found
rel
long
period
absenc
sustain
humanhuman
transmiss
led
search
local
anim
reservoir
middl
east
merscov
relat
bat
cov
replic
bat
cell
line
suggest
enter
cell
use
conserv
receptor
dipeptidyl
peptidas
also
known
discov
function
receptor
merscov
replic
either
human
bat
express
nonpermiss
cell
viru
replic
notabl
present
human
epitheli
cell
lower
respiratori
tract
absent
upper
respiratori
tract
epitheli
cell
could
explain
poor
human
human
transmiss
mer
compar
sar
investig
anim
could
sourc
zoonot
transmiss
merscov
antibodi
variou
cov
sought
sheep
cow
goat
spanish
dromedari
omani
dromedari
although
antibodi
sarscov
detect
anim
antibodi
merscov
detect
individu
spanish
dromedari
moreov
virtual
omani
dromedari
high
level
antibodi
merscov
use
camel
present
slaughter
express
detect
lower
respiratori
tract
also
upper
respiratori
tract
nasal
caviti
nasal
sampl
taken
camel
differ
age
presenc
merscov
vari
age
preval
younger
anim
age
year
clearli
virtual
camel
becom
infect
first
year
merscov
antibodi
detect
minor
peopl
work
camel
peopl
contact
camel
peopl
antibodi
recal
seriou
diseas
would
possibl
creat
vaccin
effect
camel
human
recombin
spike
protein
fragment
amino
acid
aa
full
length
aa
previous
shown
bind
bat
human
cell
may
use
candid
vaccin
human
mab
recogn
also
neutral
merscov
vitro
also
express
spike
protein
modifi
vaccinia
ankara
viru
mva
induc
viru
neutral
antibodi
mice
therefor
vaccin
may
test
camel
reduc
viru
excret
subsequ
camelhuman
transmiss
proofofconcept
trial
vaccin
dromedari
camel
immun
two
dose
mva
challeng
merscov
via
nasal
spray
devic
immun
none
control
camel
develop
antibodi
merscov
wherea
camel
given
vaccin
develop
viru
neutral
antibodi
addit
camel
vaccin
mva
show
reduc
viru
excret
upon
challeng
merscov
contrast
encourag
result
vaccin
treatment
patient
interferon
ribavirin
greatli
improv
surviv
day
vs
p
although
larger
trial
may
shown
signific
improv
efficaci
therapi
clearli
need
polymeras
hcv
least
region
known
nonnucleosid
inhibitor
nni
bind
three
region
base
deep
cleft
close
catalyt
site
nucleosid
bind
start
benzofuran
core
known
bind
one
site
pocket
thought
core
could
extend
caviti
may
possibl
captur
extra
bind
interact
could
lead
nni
improv
potenc
broader
rang
activ
differ
genotyp
start
inhous
model
polymeras
eventu
emerg
lead
candid
compound
excel
activ
genotyp
replicon
assay
ec
nm
lack
cytotox
cc
lm
also
maintain
potenc
known
nni
resist
mutat
identifi
direct
resist
select
mutat
genotyp
background
identifi
mutat
appear
reduc
viral
fit
phase
ib
proofofconcept
studi
patient
genotyp
genotyp
mg
given
daili
day
howev
two
unexpect
result
three
patient
genotyp
modest
reduct
viral
load
genotyp
patient
result
predict
vitro
potenc
explain
vivo
pharmacokinet
ii
viral
load
two
three
patient
genotyp
reduc
initi
rebound
dose
period
mutat
observ
day
studi
rais
interest
question
differenti
respons
genotyp
predict
preclin
studi
ii
mutant
viru
replic
patient
appear
debilit
vitro
iii
new
preclin
resist
studi
would
accur
predict
lack
clinic
resist
studi
incorpor
futur
nni
discoverylead
optim
protocol
pharmacodynam
investig
human
rhinoviru
inhibitor
hollow
fiber
infect
model
qin
yu
astrazeneca
r
waltham
usa
grow
human
cell
hollow
fiber
system
possibl
accur
mimic
human
pharmacokinet
one
reservoir
contain
activ
drug
cultur
medium
pump
system
control
comput
cell
infect
ad
inoculum
viru
qin
describ
use
system
investig
proteas
inhibitor
human
rhinoviru
main
factor
determin
efficaci
drug
peak
level
c
max
trough
level
c
min
first
step
determin
steadydos
level
gave
good
protect
lowest
drug
level
gave
good
protect
h
ec
concentr
keep
total
daili
dose
equival
constant
ec
concentr
daili
twice
daili
fourtim
daili
dose
simul
expect
daili
dose
gave
highest
c
max
fourtim
daili
gave
highest
c
min
daili
dose
gave
poor
activ
fourtim
daili
dose
best
activ
hollowfib
system
use
tool
investig
human
pharmacokinet
influenc
efficaci
exampl
would
load
dose
benefici
qin
conclud
establish
first
human
rhinoviru
hollow
fiber
system
three
awarde
remark
career
elion
award
present
phil
furman
earli
day
work
acyclovir
trudi
elion
mind
acyclovir
import
gamechang
antivir
may
biggest
sale
first
antivir
drug
combin
good
clinic
efficaci
truli
remark
safeti
profil
three
decad
still
stand
benchmark
safeti
today
acyclovir
prodrug
valacyclovir
use
worldwid
treat
herpesviru
infect
gener
healthi
popul
proport
resist
viru
remain
prior
acyclovir
recal
anyon
predict
antivir
could
use
clinic
three
decad
less
clinic
problem
best
antibiot
howev
phil
hardli
mention
acyclovir
focus
research
led
sofosbuvir
anoth
gamechang
time
patient
hcv
infect
award
present
denni
liotta
like
phil
denni
describ
work
led
invent
import
antivir
hiv
therapi
estim
hivposit
patient
usa
taken
drug
invent
develop
denni
chose
describ
recent
research
remark
journey
chemistri
led
new
unexpect
territori
prusoff
award
young
investig
alreadi
made
impact
antivir
field
set
continu
erica
ollmann
saphir
highli
qualifi
recipi
award
lectur
describ
viral
protein
abl
rearrang
differ
form
fulfil
differ
function
lucki
listen
mani
fine
lectur
icar
meet
year
erica
lectur
sail
straight
topten
three
excel
keynot
lectur
approv
sofosbuvir
fda
decemb
eu
januari
herald
new
era
therapi
chronic
hcv
infect
raffael
de
francesco
set
scene
overview
earli
antivir
agent
improv
cure
rate
use
ifn
could
use
due
hcv
resist
although
nucleotid
analog
develop
seem
narrow
sar
sofosbuvir
remain
approv
nucleotid
analog
michael
mann
continu
stori
give
detail
account
clinic
pictur
chang
continu
chang
rapidli
guidelin
written
rewritten
earli
new
drug
expect
includ
sofosbuvir
combin
new
inhibitor
velpatasvir
gs
activ
genotyp
hcv
strain
mutant
resist
ledipasvir
part
harvoni
seem
close
aspir
therapi
singl
pill
daili
week
give
essenti
cure
rate
patient
genotyp
hcv
produc
virion
daili
untreat
patient
great
capac
gener
resist
mutant
remark
scientif
achiev
third
keynot
speaker
armand
sprecher
gave
amaz
account
remark
organ
san
msf
day
initi
alert
msf
open
ebola
treatment
unit
etu
impress
achiev
ebola
outbreak
exact
huge
human
cost
howev
greatli
admir
healthcar
worker
respond
emerg
even
though
put
live
risk
armand
briefli
mention
clinic
trial
includ
favipiravir
publish
result
treat
patient
moder
low
baselin
level
ebola
viru
gener
rapidli
decreas
viral
load
day
start
therapi
ebola
outbreak
continu
patient
routin
viral
load
measur
unusu
viral
load
decreas
day
enter
ebola
treatment
center
viral
load
data
gather
clinic
trial
give
best
indic
favipiravir
provid
benefit
ebola
patient
armand
end
present
happier
note
follow
suit
report
although
ebola
outbreak
continu
sign
progress
world
health
organ
report
ebola
situat
report
august
confirm
case
ebola
viru
diseas
evd
report
week
august
guinea
sierra
leon
lowest
weekli
total
report
sinc
march
mark
third
consecut
declin
weekli
case
incid
report
warn
continu
difficulti
face
polici
contain
individu
known
contact
lost
followup
ebola
infect
confirm
intens
effort
trace
contact
howev
pleas
see
report
mention
trial
ebola
suffit
ring
vaccin
trial
guinea
cluster
